

# Carl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2874660/publications.pdf>

Version: 2024-02-01

31  
papers

5,712  
citations

567281

15  
h-index

501196

28  
g-index

31  
all docs

31  
docs citations

31  
times ranked

7707  
citing authors

#	ARTICLE	IF	CITATIONS
1	The year in cardiovascular medicine 2021: dyslipidaemia. <i>European Heart Journal</i> , 2022, , .	2.2	9
2	Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. <i>Progress in Cardiovascular Diseases</i> , 2022, 73, 32-40.	3.1	19
3	LDL-C Estimation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 542-544.	2.8	5
4	Managing Atherosclerotic Cardiovascular Risk in Young Adults. <i>Journal of the American College of Cardiology</i> , 2022, 79, 819-836.	2.8	72
5	The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. <i>Journal of Clinical Lipidology</i> , 2021, 15, 33-60.	1.5	105
6	How low is safe? The frontier of very low (&lt;30 mg/dL) LDL cholesterol. <i>European Heart Journal</i> , 2021, 42, 2154-2169.	2.2	28
7	In Reply“Coronary Artery Calcium Scores I and II. <i>Mayo Clinic Proceedings</i> , 2021, 96, 262-263.	3.0	0
8	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2660-2670.	3.0	7
9	Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit. <i>Journal of Clinical Lipidology</i> , 2021, , .	1.5	2
10	Modeling the Recommended Age for Initiating Coronary Artery Calcium Testing Among At-Risk Young Adults. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1573-1583.	2.8	31
11	PCSK9 inhibition for acute arterial events: more than LDL lowering. <i>European Heart Journal</i> , 2021, 42, 4830-4832.	2.2	2
12	How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 16.	1.0	1
13	Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 151-157.	4.9	3
14	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. <i>Journal of the American Heart Association</i> , 2020, 9, e018189.	3.7	4
15	When a “normal” cholesterol level is not normal: Exposing an unusual presentation of familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2020, 14, 414-418.	1.5	0
16	HOPE for Rational Statin Allocation for Primary Prevention: A Coronary Artery Calcium Picture Is Worth 1000 Words. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1740-1749.	3.0	10
17	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. <i>Journal of Clinical Lipidology</i> , 2019, 13, 860-872.	1.5	79
18	JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product. <i>Journal of Clinical Lipidology</i> , 2019, 13, 345-355.	1.5	0

#	ARTICLE	IF	CITATIONS
19	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019, 13, 374-392.	1.5	315
20	Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019, 13, 525-537.	1.5	45
21	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. <i>Journal of the American College of Cardiology</i> , 2019, 73, e285-e350.	2.8	1,550
22	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019, 139, e1082-e1143.	1.6	2,380
23	Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2017, 11, 880-890.	1.5	85
24	Consensus between the American College of Cardiology and the National Lipid Association on the use of non-statin therapy for atherosclerotic cardiovascular disease prevention. <i>Journal of Clinical Lipidology</i> , 2016, 10, 458-461.	1.5	2
25	2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. <i>Journal of the American College of Cardiology</i> , 2016, 68, 92-125.	2.8	371
26	Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 468-495.	1.2	45
27	Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 905-914.	1.5	54
28	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. <i>Journal of Clinical Lipidology</i> , 2016, 10, 33-57.	1.5	39
29	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. <i>Journal of Clinical Lipidology</i> , 2016, 10, 15-32.	1.5	17
30	Clinical lipidology: A subspecialty whose time has come. <i>Journal of Clinical Lipidology</i> , 2015, 9, 634-639.	1.5	2
31	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015, 9, S1-S122.e1.	1.5	430